What the Trial Compared
Two once-daily pills that work through the same hormone pathway have now been tested against each other, and the comparison was not close on the endpoints the trial measured.
ACHIEVE-3 was a phase 3, 52-week, randomized, open-label trial enrolling 1,698 adults with type 2 diabetes inadequately controlled on metformin, across 131 medical centers in Argentina, China, Japan, Mexico and the United States. Participants were assigned to one of four arms: orforglipron at 12 mg or 36 mg, or oral semaglutide at 7 mg or 14 mg, according to Eli Lilly's announcement of the results, published in The Lancet.
All participants started at a low dose and stepped up at four-week intervals to their assigned maintenance dose. The primary objective was to show that orforglipron was non-inferior to oral semaglutide for A1C reduction at 52 weeks. It cleared that bar and went further, achieving superiority on the primary endpoint and all key secondary endpoints.
"ACHIEVE-3 gives us the first head-to-head comparison between two oral GLP-1 receptor agonist therapies in adults with type 2 diabetes, and the differences were clinically meaningful," said Julio Rosenstock, MD, clinical professor of medicine at the University of Texas Southwestern Medical Center and the trial's lead investigator.
One structural difference between the drugs matters for daily life. Orforglipron is a small molecule taken without food or water restrictions. Oral semaglutide is a peptide that must be taken on an empty stomach with a small sip of water, followed by a 30-minute wait before eating or drinking.
What the Numbers Showed
The gap appeared on both measures the trial was built around.
On blood sugar, participants taking 36 mg of orforglipron saw A1C fall by close to 2 percentage points, compared with roughly 1.5 points for those on 14 mg of oral semaglutide, as Scientific American reported.
On weight, the 36 mg orforglipron group lost 9.2 percent of body weight, roughly 19.7 pounds, against 5.3 percent, roughly 11.0 pounds, for oral semaglutide at 14 mg, according to Pharmacy Times. The lower orforglipron dose of 12 mg produced 6.7 percent weight loss, about 13.7 pounds.
The trial also reported improvements from baseline in cardiovascular risk factors including total cholesterol, triglycerides, and systolic blood pressure. Those are risk markers, not outcomes, and the distinction matters for reasons the next section addresses.
The Trade-Off in Tolerability
The result was not uniformly favorable, and the part that was not deserves equal billing.
More participants stopped or discontinued forglipron because of adverse events. Discontinuation rates were 8.7 percent at the 12 mg dose and 9.7 percent at 36 mg, compared with 4.5 percent and 4.9 percent for oral semaglutide at 7 mg and 14 mg. That is roughly double.
The most common adverse events were the same across both drugs and familiar for the class: nausea, diarrhea, vomiting, dyspepsia and decreased appetite. Lilly described orforglipron's overall safety and tolerability profile as consistent with previous trials.
For a patient, that combination reads as a genuine trade-off rather than a clean win. Greater average benefit came alongside a higher chance of stopping. Averages also conceal individual variation, and a person who cannot tolerate a drug receives none of its average benefit.
What Has Not Been Established
Several limitations need to sit here rather than at the end.
The trial was open-label, meaning participants and investigators knew which drug was being taken. That design is common in trials comparing agents with different administration requirements, but it can influence reported outcomes, particularly subjective ones such as appetite and gastrointestinal symptoms.
The trial ran 52 weeks. It does not establish durability beyond a year, and it does not measure cardiovascular outcomes such as heart attack, stroke or cardiovascular death. Improvements in cholesterol, triglycerides and blood pressure are encouraging surrogate measures, but surrogate improvement has not always translated into outcome benefit in drug development.
The population studied was adults with type 2 diabetes inadequately controlled on metformin. The findings do not automatically extend to people with type 2 diabetes on other regimens, to people without diabetes taking these drugs for weight, or to people taking injectable GLP-1 medications, which were not in this trial.
The study was funded by Eli Lilly, orforglipron's manufacturer. Daniel Drucker, an endocrinologist at the University of Toronto who was not involved in the trial, called the results "very encouraging" for safety and efficacy in type 2 diabetes while noting he was awaiting further results in people with obesity. Drucker has previously consulted for Novo Nordisk, Eli Lilly and other companies developing weight-loss medications.
What This Means for Patients Now
Orforglipron is already available in the United States, but for a different indication.
The FDA approved it as Foundayo on April 1, 2026, for weight management in adults with obesity or overweight with weight-related conditions. Lilly has submitted the drug to regulators in more than 40 countries and said a U.S. submission for type 2 diabetes was planned for later in 2026. Until that is approved, prescribing it specifically for diabetes would be off-label.
Nothing in this trial is a reason to stop or switch a medication on your own. Anyone currently taking oral semaglutide with good glycemic control has a result that works. Anyone whose A1C is not at goal has a reason to discuss options with a clinician, and this trial is one input among several.
Cost and coverage will shape access more than efficacy data will. Commercial coverage for GLP-1 medications has tightened, and a newer agent typically faces tighter formulary placement than an established one.
MedicalDaily will report the FDA's decision on orforglipron for type 2 diabetes, results from the obesity program, and any cardiovascular outcomes data as it becomes available.
Frequently Asked Questions
What did the trial find? Orforglipron produced greater A1C reduction and greater weight loss than oral semaglutide across the doses studied in 1,698 adults with type 2 diabetes over 52 weeks.
How much more weight loss? At the highest doses compared, 9.2 percent of body weight with orforglipron versus 5.3 percent with oral semaglutide.
Were there downsides? Yes. Roughly twice as many participants stopped orforglipron because of adverse events, mostly gastrointestinal.
Who was studied? Adults with type 2 diabetes inadequately controlled on metformin. The findings do not automatically apply to other populations.
Did it show heart benefit? No. It reported improvements in cholesterol, triglycerides and blood pressure, which are risk markers. Cardiovascular outcomes were not measured.
Can I get orforglipron for diabetes now? It is approved in the U.S. for weight management as Foundayo. A U.S. submission for type 2 diabetes was planned for later in 2026.
Who funded the study? Eli Lilly, which makes orforglipron.
